Study Comparing Esomeprazole and ASA Combined Together as One Capsule Versus These Medications Taken Separately

Model scores of the 29,894 trials active now.

Model score 2% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (176 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: patientsdiseasecombinationkidneyor equal
  Phrases that lowered it: tabletkgcrossoverbioequivalence20
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Design: crossover (lowers risk) · Design
• Phase: 1 (lowers risk) · Design
• Primary purpose: not given (lowers risk) · Design
• Sponsor's past termination rate: 7.0% (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 376 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 9.1% (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 23741 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 728 (raises risk) · Sponsor's track record
• Blinding: none (lowers risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study Comparing Esomeprazole and Acetylsalicylic Acid (ASA) Combined Together as One Capsule Versus These Medications Taken Separately NCT00998075 · started 2009 · scored riskier than 0% of active trials completed
• Study Comparing a Fixed-Dose Capsule of Esomeprazole 40mg and LDA 325mg With Free Combination NCT00688428 · started 2008 · scored riskier than 1% of active trials completed
• A Healthy Female and Male Volunteers Aspirin Study NCT01448031 · started 2011 · scored riskier than 1% of active trials completed
• Randomized, Crossover Bioequivalence Study of PL-ASA Versus Immediate Release Aspirin in Healthy Volunteers. NCT05055752 · started 2020 · scored riskier than 1% of active trials completed
• Bioequivalence of Single Dose Fast Release Aspirin (1000 mg) Tablet Versus Single Dose of Two 500 mg Fast Release Aspirin Tablets NCT03056703 · started 2014 · scored riskier than 1% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.